Readington-based Merck & Co.’s Fosamax, Novartis AG’s Reclast and similar medicines for thin, weak bones may produce severe joint and muscle pain, U.S. regulators said.

Health-care professionals should consider discontinuing use of the treatments, called bisphosphonates, in patients who develop pain, the Food and Drug Administration said today in a statement on its Web site. The side effect is already listed in the drugs’ prescribing information, though it may be missed by doctors, the FDA said.

About 10 million Americans, mostly older women, have the loss of bone density known as osteoporosis. Demand for new, more convenient treatment options has increased as the U.S. population ages. Market leader Fosamax, with sales of $3.1 billion in 2006, will face generic competition this year. Reclast, a 15-minute infusion given once a year, was approved by the FDA in August.

Procter & Gamble Co.’s Actonel and Didronel, Novartis’s Aredia and Zometa, Sanofi-Aventis SA’s Skelid, and Boniva, sold by Roche Holding AG and GlaxoSmithKline Plc, were also named in the FDA’s statement. The agency plans to provide doctors with more information after it reviews the risk of joint pain associated with the products during the next six months.

The FDA said in October that it was reviewing bisphosphonates for a possible link to irregular heart rhythm after a study showed that women taking Fosamax or Reclast were more likely to develop serious cases of atrial fibrillation.



We're here to help!

We live by our creed of "helping those who need it most" and have helped thousands of clients get the justice they desperately needed and deserved. If you feel you have a case or just have questions please contact us for a free consultation. There is no risk and no fees unless we win for you.

Fields marked    may be required for submission.
  1. I'm an attorney

Fosamax linked to serious health risks

Fosamax is a type of medication known as a bisphosphonate, prescribed for the treatment of bone loss and...

Beasley Allen attorney Chad Cook selected to help lead...

Wesley Chadwick Cook has been selected to serve on Plaintiffs Steering Committee (PSC) for the...

Fosamax

WHAT IS FOSAMAX? Fosamax (alendronate sodium) manufactured by (Merck & Company) it belongs to a...

New Fosamax safety label warns of bone problems

The osteoporosis drug Fosamax has updated the Warnings, Adverse Reactions, and Patient Information...

Merck readies for first Fosamax trial

Merck & Co on Tuesday is slated to fight the first of numerous U.S. lawsuits brought by patients who...

Chad Cook on Fosamax Litigation

Chad Cook, lead Fosamax attorney, discusses ongoing Fosamax litigation. Recent studies demonstrate a...

A special thanks

A special thanks to your law firm and staff for all the work done on the Vioxx case. The settlement could not have come at a better time for my family and myself. I thank you for a job well done!

—George